Shvartsman G I, Skoromets A A, Zhivolupov S A, Kurushina O V, Karpov S M, Baranova N S, Nesterova M V, Smagina I V, Prokopenko S V, Antipenko E A, Novikova L B
Mechnikov North-Western State Medical University, St. Petersburg, Russia.
Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(8):88-94. doi: 10.17116/jnevro202212208188.
Obtaining additional data on the efficacy and safety of the drug Prospekta in the treatment of moderate cognitive impairment (MCI) and asthenia in patients with cerebrovascular disease (CVD).
A prospective observational study in more than 40 Russian cities enrolled 232 patients (mean age 61.5±10.0 years) with mild cognitive impairment (MCI), asthenia on ongoing basic nootropic therapy. The presence of MCI was confirmed by the Montreal Cognitive Assessment Scale (MoCA), asthenia - by 10-point Visual Analog Scale (VAS). All patients were prescribed the nootropic medication Prospekta 2 tablets 2 times a day for 8 weeks in addition to the therapy they received. Ultrasound Doppler sonography of the main arteries of the head and magnetic resonance imaging (MRI) of the brain were also assessed. At the end of treatment, the Clinical Global Impression Efficacy Index (CGI-EI) was assessed and the safety of the treatment was evaluated.
The baseline severity of cognitive impairment according to the MoCA scale was 21.6 points, severity of asthenia according to the VAS was 6.3 points. According to Doppler flowmetry findings, hemodynamically significant stenosis was revealed in 105 (49.3%) patients, and narrowing of the main vessels without changes in hemodynamic parameters was revealed in 108 (50.7%) patients. According to MRI results, single vascular lesions in the brain matter were detected in 102 (44.0%) patients. The medications with nootropic effect were administered to 144 (62.1%) patients. A positive therapeutic response as improvement of cognitive functions was seen in 93.3% of patients after 8 weeks of taking Prospekta, including 39.4% of patients who had cognitive functions restored to the normal level. No side effects were registered during the observational study.
The nootropic medication Prospekta is effective and safe in treatment of MCI in patients with asthenia with CVD, and improves cognitive function in patients with asthenia with CVD, both in monotherapy and in combination with other nootropic agents.
获取关于药物Prospekta治疗脑血管疾病（CVD）患者中度认知障碍（MCI）和虚弱的疗效及安全性的更多数据。
在俄罗斯40多个城市开展的一项前瞻性观察性研究纳入了232例患者（平均年龄61.5±10.0岁），这些患者患有轻度认知障碍（MCI）且在进行基础促智治疗时伴有虚弱。MCI的存在通过蒙特利尔认知评估量表（MoCA）确认，虚弱通过10分视觉模拟量表（VAS）确认。除接受的治疗外，所有患者均被开具促智药物Prospekta，每日2次，每次2片，持续8周。还对头颈部主要动脉进行了超声多普勒检查以及脑部磁共振成像（MRI）评估。治疗结束时，评估临床总体印象疗效指数（CGI-EI）并评价治疗安全性。
根据MoCA量表，认知障碍的基线严重程度为21.6分，根据VAS，虚弱的严重程度为6.3分。根据多普勒血流测定结果，105例（49.3%）患者存在血流动力学显著狭窄，108例（50.7%）患者存在主要血管狭窄但血流动力学参数无变化。根据MRI结果，102例（44.0%）患者在脑实质中检测到单个血管病变。144例（62.1%）患者接受了具有促智作用的药物治疗。服用Prospekta 8周后，93.3%的患者出现了认知功能改善的积极治疗反应，其中39.4%的患者认知功能恢复到正常水平。在观察性研究期间未记录到副作用。
促智药物Prospekta治疗伴有虚弱的CVD患者的MCI有效且安全，并且无论是单药治疗还是与其他促智药物联合使用，均可改善伴有虚弱的CVD患者的认知功能。
